Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension

This study has been completed.

First Received: May 28, 2003 Last Updated: August 4, 2008 History of Changes

Sponsor:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00061503

Purpose

The primary objective of this study is to describe the effect of TRAVATAN 0.004% Ophthalmic Solution on aqueous humor dynamics in subjects with a clinical diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).

Condition	Intervention	Phase
Glaucoma Ocular Hypertension	Drug: Travoprost	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Double-Masked, Placebo-Controlled, Paired Comparison Study of the Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension

Resource links provided by NLM:

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma High Blood Pressure

Drug Information available for: Travoprost

U.S. FDA Resources

Further study details as provided by Alcon Research:

Study Start Date:	April 2003
Study Completion Date:	March 2004
Primary Completion Date:	March 2004 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Subjects 18 years of age or older
of either sex
of any race
diagnosed with ocular hypertension or open angle glaucoma

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00061503

Locations

United States, Nebraska
Alcon Call Center
Call for Details, Nebraska, United States

Sponsors and Collaborators

Alcon Research

More Information

No publications provided

Study ID Numbers:	C-01-55
Study First Received:	May 28, 2003
Last Updated:	August 4, 2008
ClinicalTrials.gov Identifier:	NCT00061503 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Alcon Research:

Glaucoma
Ocular Hypertension

Additional relevant MeSH terms:

Glaucoma
Therapeutic Uses
Eye Diseases
Vascular Diseases
Cardiovascular Diseases
Cardiovascular Agents

Antihypertensive Agents
Pharmacologic Actions
Travoprost
Ocular Hypertension
Hypertension

ClinicalTrials.gov processed this record on November 05, 2009